Weston Nichols Net Worth

Weston Nichols biography

Weston A. Nichols Ph.D. serves as Independent Director of the Company. Dr. Nichols has been the Founder and Managing Partner of Lynx1 Capital, a biotechnology focused investment fund. From April 2016 to March 2020, Dr. Nichols served as an analyst for Perceptive Advisors, a life sciences focused investment firm. From January 2015 to April 2016, Dr. Nichols was an analyst at Balyasny Asset Management, an investment management firm, and from May 2014 to December 2014, he was a biotechnology equity research associate at SunTrust Robinson Humphrey. Dr. Nichols holds a B.S. in biological engineering from Cornell University, and a Ph.D. in neuroscience from Caltech. Dr. Nichols’ experience as venture capitalist in the life science industry contributed to our board of directors’ conclusion that he should serve as a director of our company.

What is the salary of Weston Nichols?

As the Independent Director of Crinetics Pharmaceuticals Inc, the total compensation of Weston Nichols at Crinetics Pharmaceuticals Inc is $229,250. There are 11 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.

How old is Weston Nichols?

Weston Nichols is 35, he's been the Independent Director of Crinetics Pharmaceuticals Inc since 2018. There are 18 older and no younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.

What's Weston Nichols's mailing address?

Weston's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.

Insiders trading at Crinetics Pharmaceuticals Inc

Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen et Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.

What does Crinetics Pharmaceuticals Inc do?

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Crinetics Pharmaceuticals Inc executives and stock owners

Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• R. Scott Struthers,
  President, Chief Executive Officer, Director
• Alan Krasner,
  Chief Medical Officer
• Marc Wilson,
  Chief Financial Officer
• Dr. R. Scott Struthers Ph.D.,
  Founder, Pres, CEO & Director
• Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
  Chief Devel. Officer
• Marc J. C. Wilson,
  CFO & Sec.
• Stephanie Okey,
  Independent Director
• Wendall Wierenga,
  Independent Chairman of the Board
• Matthew Fust,
  Independent Director
• Jeff E. Knight,
  Chief Operating Officer
• Stephen Kaldor,
  Independent Director
• Weston Nichols,
  Independent Director
• Peter Trainer,
  Vice President - Clinical Endocrinology
• Camille Bedrosian,
  Independent Director
• Adriana Cabre,
  Vice President of Human Resources
• Ajay Madan,
  Chief Development Officer
• Chris Robillard M.B.A.,
  Chief Bus. Officer
• James Hassard,
  Chief Commercial Officer
• Dr. Alan S. Krasner M.D.,
  Chief Medical Officer
• Adriana Cabre M.B.A.,
  Chief HR Officer
• Kevin Capps,
  Head of Intellectual Property
• Dr. Alan S. Krasner,
  Chief Medical Officer
• Garlan Adams,
  Gen. Counsel
• Dr. Stephen F. Betz Ph.D.,
  Founder & Chief Scientific Officer
• Dr. Yun-Fei Zhu,
  Founder & VP of Chemistry
• Jeff E. Knight,
  Chief Operating Officer
• Advisors Llcperceptive Life...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Venture Capital V, L.P.Vers...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Venture Capital V, L.P.Vers...,
  
• Capital Viii, Llc Vivo Capi...,
  
• James Hassard,
  Chief Commercial Officer
• Jack Nielsen,
  Director
• Coelho Rogerio Vivaldi,
  
• Dana Pizzuti,
  Chief Med and Dev Officer
• Stephen F. Betz,
  Chief Scientific Officer
• Caren Deardorf,